Mitral Stenosis
Mitral stenosis is:
- Narrowing of the mitral valve orifice, leading to a fixed-cardiac output state with a pressure-overloaded (and typically subsequently volume-overloaded) left atrium
Normal area is >4cm2.
MS is classified:
- Into mild, moderate, or severe
Symptoms typically only present in moderate-severe MS. - Based on echocardiographic findings
Using either:- Mean pressure gradient over the valve
- Pressure half-time
- Valve area
Measurement | Mild | Moderate | Severe |
---|---|---|---|
MPG | <5mmHg | 6-10mmHg | >10mmHg |
Pressure half-time | <139ms | 140-219ms | >220ms |
Valve area | 1.6-2.0cm2 | 1.5-1cm2 | <1cm2 |
Epidemiology and Risk Factors
Important associations:
- Rheumatic fever
- Pregnancy
Leads to early presentation with symptoms due to ↑ cardiovascular work and circulating volume.- Fixed CO-state leads to ↑ pulmonary hypertension
- Cardiac failure typically occurs in third-trimester in patients with moderate-severe disease
Pathophysiology
- ↑ Pressure gradient across the mitral valve
Flow across mitral valve becomes the prime determinant of ventricular filling.- This leads to a fixed cardiac output state because:
- ↓ Afterload does not improve subsequent ventricular filling
- ↑ Contractility cannot improve output if the ventricle is not adequately filled prior to contraction
- This leads to a fixed cardiac output state because:
- High LAP and PCWP
- Development of class II pulmonary hypertension
- Consequential RV dilation and RV failure
- Low LVEDV and LVEDP
- Typically results in LV remodelling and ↓ systolic function
Aetiology
Causes include:
- Rheumatic Most common cause.
- Rarer aetiology in developed countries
- Typically worsens at the rate of 0.1-0.3cm2/year
More rapid in cases of repeated infection.
Assessment
MS is typically well tolerated and has a long asymptomatic period that continues until LA dilation fails to compensate and pulmonary HTN ensures, leading to:
- Pulmonary oedema
- Fatigue
History
Examination
Diagnostic Approach and DDx
Investigations
Management
Goals of management
Resuscitation:
Specific therapy:
- Pharmacological
- Rate control of AF
- β-blockers are mainstay of treatment
- Diuresis and vasodilators (e.g. nitrates) for failure
- Rate control of AF
- Procedural
- MVR
- Percutaneous mitral commissurotomy
- Balloon dilatation
- Physical
Supportive care:
Disposition:
Preventative:
Anaesthetic Considerations
- C
- Maintain sinus rhythm
- Low-normal HR to facilitate diastolic filling
- Maintain preload
Delicate balance.- Volume required due to diastolic dysfunction
- Excessive volume will worsen pulmonary oedema
- Maintain afterload
As CO is fixed, reduced SVR will ↓ CPP. - Prevent ↑ in PVR
Right heart function may be tenuous in the setting of pre-existing PHTN. - Systolic function often suppressed after replacement
- Highly sensitive to preload changes
In mixed valvular disease, management should prioritise the most haemodynamically significant lesion. That said, in general:
- In mixed AS and MS
Progression is typically similar to that with pure MS and pulmonary hypertension. Considerations include:- Two fixed output lesions in series
- Generally high burden of pulmonary disease
- AS severity may be underestimated due to the ↓ AV flow
- In mixed MS and MR
Competing haemodynamic disease that is a common conundrum in rheumatic disease. In general:- In asymmetric disease, prioritise the most significant lesion
- Otherwise aim maintenance of stable pre-induction haemodynamic parameters, i.e.:
- Maintain normal afterload
- Maintain normal HR
- Maintain normal contractility
- Avoid ↑ PVR
- Provide adequate preload
ICU Considerations
Following MV repair or replacement:
- Maintain preload due to existing diastolic dysfunction
- Reduce afterload to improve forward flow
- Right heart support may be required
Complications
- AF
Due to atrial dilation.- Leads to worsening symptoms due to:
- Reduced diastolic time
- Reduced atrial kick
- Leads to worsening symptoms due to:
- Pulmonary hypertension
Due to ↑ LAP. - Right heart failure
Due to prolonged period of pulmonary hypertension.
Prognosis
- Death
Following symptom development there is:- 80% 1-year survival
- 15% 10-year survival
References
- Holmes K, Gibbison B, Vohra HA. Mitral valve and mitral valve disease. BJA Educ. 2017;17(1):1-9. doi:10.1093/bjaed/mkw032